---
figid: PMC4982433__12957_2016_969_Fig3_HTML
figtitle: Signalling pathway and targeted therapy in gastric cancer
organisms:
- NA
pmcid: PMC4982433
filename: 12957_2016_969_Fig3_HTML.jpg
figlink: /pmc/articles/PMC4982433/figure/Fig3/
number: F3
caption: 'Signalling pathway and targeted therapy in gastric cancer. Percentages signify
  the overall molecular characteristics in the disease: FGFR2 amplification (9 %),
  VEGF/VEGFR overexpression (36–40 %), EGFR amplification and overexpression (27–44 %),
  HER2 amplification and overexpression (7–34 %), c-MET amplification (10–15 %), kRAS
  mutation (2–20 %), Raf mutation (0–3 %), PI3K mutation (4–36 %), phospho-Akt expression
  (29–86 %), phospho-mTOR expression (60–88 %), PTCH1 overexpression (16%), SMO overexpression
  (12%), and HER3 mutations (10%, not shown). *No clinical trials of these agents
  have yet been reported in gastric cancer. ‡No known numbers or percentages for these
  genes and pathways. Abbreviations: EGFR epidermal growth factor receptor, FGFR fibroblast
  growth factor receptor, GLI glioma-associated oncogene family zinc finger 1, HDAC
  histone deacetylase, HER human epidermal growth factor receptor, HGF hepatocyte
  growth factor, Hh Hedgehog, IGFR insulin-like growth factor receptor, MMP matrix
  metalloproteinase, mTOR mammalian target of rapamycin, PDGFR platelet-derived growth
  factor receptor, Ptch-1 protein patched homolog 1, Smo smoothened, VEGF vascular
  endothelial growth factor, VEGFR vascular endothelial growth factor receptor (reproduced
  with permission from Wadhwa, R. et al. Nat. Rev. Clin. Oncol. 10, 643–655 (2013)
  [])'
papertitle: 'Gastric biomarkers: a global review.'
reftext: Nick Baniak, et al. World J Surg Oncol. 2016;14:212.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9712005
figid_alias: PMC4982433__F3
figtype: Figure
organisms_ner:
- Homo sapiens
- Danio rerio
redirect_from: /figures/PMC4982433__F3
ndex: 47d040ec-dec7-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4982433__12957_2016_969_Fig3_HTML.html
  '@type': Dataset
  description: 'Signalling pathway and targeted therapy in gastric cancer. Percentages
    signify the overall molecular characteristics in the disease: FGFR2 amplification
    (9 %), VEGF/VEGFR overexpression (36–40 %), EGFR amplification and overexpression
    (27–44 %), HER2 amplification and overexpression (7–34 %), c-MET amplification
    (10–15 %), kRAS mutation (2–20 %), Raf mutation (0–3 %), PI3K mutation (4–36 %),
    phospho-Akt expression (29–86 %), phospho-mTOR expression (60–88 %), PTCH1 overexpression
    (16%), SMO overexpression (12%), and HER3 mutations (10%, not shown). *No clinical
    trials of these agents have yet been reported in gastric cancer. ‡No known numbers
    or percentages for these genes and pathways. Abbreviations: EGFR epidermal growth
    factor receptor, FGFR fibroblast growth factor receptor, GLI glioma-associated
    oncogene family zinc finger 1, HDAC histone deacetylase, HER human epidermal growth
    factor receptor, HGF hepatocyte growth factor, Hh Hedgehog, IGFR insulin-like
    growth factor receptor, MMP matrix metalloproteinase, mTOR mammalian target of
    rapamycin, PDGFR platelet-derived growth factor receptor, Ptch-1 protein patched
    homolog 1, Smo smoothened, VEGF vascular endothelial growth factor, VEGFR vascular
    endothelial growth factor receptor (reproduced with permission from Wadhwa, R.
    et al. Nat. Rev. Clin. Oncol. 10, 643–655 (2013) [])'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HGF
  - IL6
  - SOS1
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - PDGFRB
  - PDGFRA
  - EGFR
  - IGF1R
  - FGFR2
  - KDR
  - FLT1
  - FLT4
  - ERBB2
  - MET
  - SMO
  - SMOX
  - PTCH1
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - GLI1
  - PDK1
  - PDPK1
  - RAF1
  - RNASE3
  - AKT1
  - AKT2
  - AKT3
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - MTOR
  - KMT2A
  - EZH2
  - KMT2C
  - HDAC9
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC6
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - vegfaa
  - egfra
  - her1
  - fgfr2
  - her2
  - met
  - smo
  - ptch1
  - ptch2
  - rab1ab
  - gli
  - pdk1
  - raf1a
  - mtor
  - kmt2a
  - ezh2
  - Perifosine
  - Dovitinib
  - Regorafenib
  - BMS833923
  - Cancer
  - Lung cancer
---
